TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›JSPR›Financials
Annual statements · SEC XBRL · FY2019 – FY2025

Jasper Therapeutics, Inc. (JSPR) financials

Income statement

Jasper Therapeutics, Inc. (JSPR) income statement, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income$2.90M-$20.7M$2.90M-$51.2M-$68.9M-$76.2M-$83.9M
Net income—-$31.7M-$30.6M-$37.7M-$64.5M-$71.3M-$75.8M
EPS (diluted)—-$5.17-$2.69-$10.33-$6.18-$4.89-$3.95

Cash flow

Jasper Therapeutics, Inc. (JSPR) cash flow, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow—-$18.3M-$33.7M-$45.9M-$52.1M-$62.6M-$77.2M

Balance sheet

Jasper Therapeutics, Inc. (JSPR) balance sheet, annual, from SEC filings
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$1.21M$19.8M$84.7M$38.3M$86.9M$71.6M$28.7M
Total assets$102M$23.4M$93.7M$48.4M$94.9M$79.9M$35.8M
Total liabilities$3.61M$14.6M$24.1M$12.4M$16.5M$18.2M$31.6M
Shareholders' equity-$4.73M-$35.1M$69.5M$36.0M$78.4M$61.7M$4.15M
Retained earnings$2.04K-$36.8M-$67.5M-$105M-$170M-$241M-$317M
Shares (wtd avg diluted)—2.77M11.4M3.65M10.4M14.6M19.2M

Every figure is extracted from Jasper Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

Does JSPR pay a dividend?
Jasper Therapeutics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full JSPR analysis — verdict, score & filings →Is JSPR a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.